MedTrace Logo

Evaluation of Biomarkers of COPD Exacerbation

NCT03609541 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2022-07-06

No results posted yet for this study

Summary

Serum amlyoid A (SAA) was shown to act as biomarker for exacerbation of chronic obstructive pulmonary disease (AE-COPD). It seems that SAA triggers chronic inflammation by binding to ALX/PFR2 receptor. In contrast, lipoxin A4 seems to inhibit the inflammatory processes by binding to ALX/PFR2 receptor. A small trial has already demonstrated an imbalance between SAA and lipoxin A4 during AE-COPD. This study evaluates SAA level and SAA/lipoxin A4 ratio in patients with stable COPD and AE-COPD.

Conditions

  • SAA Level and SAA/Lipoxin A4 Ratio

Sponsors & Collaborators

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Daniela Gompelmann, MD · Thoraxklinik University of Heidelberg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03609541 on ClinicalTrials.gov